ANAB - アナプティスバイオ (AnaptysBio Inc.) アナプティスバイオ

 ANABのチャート


 ANABの企業情報

symbol ANAB
会社名 AnaptysBio Inc (アナプティスバイオ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アナティスバイオ(AnaptysBio Inc.)は米国の生物技術会社である。同社は炎症および免疫腫瘍学における満たされていない医療ニーズに焦点を当てた抗体製品候補の開発に従事する。同社は、抗体産生の自然過程をインビトロで複製するように設計された抗体発見技術プラットフォームを使用して、その製品候補を開発する。その製品パイプラインには、未治療の医療ニーズを伴う重度の炎症性障害を治療するために開発されているANB020とANB019が含まれる。ANB020製品候補は、インターロイキン-33の活性を阻害する抗体であり、重度の成人喘息および重度の成人のピーナッツアレルギーの治療に使用される。同社は、一般化した膿疱性乾癬(GPP)および掌蹠膿疱性乾癬(PPP)と呼ばれる稀な炎症性疾患の治療のために、インターロイキン36受容体を阻害する抗体ANB019製品候補の開発に従事する。   アナプティスバイオは米国のバイオ医薬品企業。臨床段階で、炎症の治療に関連する抗体医薬品の開発に従事。同社は体細胞超変異を用いる抗原結合物質を生成するプラットフォ―ムを開発、試験管内で抗体生成のプロセスを再現する。医療ニ―ズはあるが治療法がまだない炎症の分野に専念する。本社所在地はカリフォルニア州サンディエゴ。   Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
本社所在地 10421 Pacific Center Court Suite 200 San Diego CA 92121 USA
代表者氏名 Hamza Suria ハムザスリア
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 858-362-6295
設立年月日 38657
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 60人
url www.anaptysbio.com
nasdaq_url https://www.nasdaq.com/symbol/anab
adr_tso
EBITDA EBITDA(百万ドル) -46.19900
終値(lastsale) 90.395
時価総額(marketcap) 2172774988.145
時価総額 時価総額(百万ドル) 2284.503
売上高 売上高(百万ドル) 3.00000
企業価値(EV) 企業価値(EV)(百万ドル) 228.214
当期純利益 当期純利益(百万ドル) -37.06000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AnaptysBio Inc revenues decreased from $7M to $0K. Net loss increased from $14.1M to $28.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing increase of 45% to $20.7M (expense) General and administrative - Balancing increase of 60% to $4.6M (expense).

 ANABのテクニカル分析


 ANABのニュース

   AnaptysBio secures $20M milestone payment from GSK after JEMPERLI FDA approval  2021/08/17 20:52:43 Seeking Alpha
   FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors  2021/08/17 20:32:00 Intrado Digital Media
SAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSKs JEMPERLI (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.
   Global Netherton Syndrome Market 2021-2030 Featuring Major Players - Lifemax Laboratories and AnaptysBio  2021/08/12 08:58:00 Intrado Digital Media
Dublin, Aug. 12, 2021 (GLOBE NEWSWIRE) -- The "Netherton Syndrome Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com''s offering. This ''Netherton Syndrome - Market Insights, Epidemiology, and Market Forecast - 2030'' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Netherton Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Netherton Syndrome Epidemiology The Netherton Syndrome epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken. Key Findings The disease epidemiology covered in the report provides historical and forecasted Netherton Syndrome epidemiology segmented as the prevalent population of Netherton Syndrome and severity-specific cases of Netherton Syndrome.
   Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies  2021/08/10 00:00:00 Benzinga
Los Angeles, USA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies Approximately 10+ key companies are developing therapies for Peanut Allergy treatment. DBV Technologies has its drug candidates in the most advanced stage. The use of new biological compounds is considered to have the potential to treat the disease, which is expected to improve the treatment method in Peanut Allergy patients. DelveInsight''s " Peanut Allergy Pipeline Insight " report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Peanut Allergy pipeline landscapes. It comprises Peanut Allergy pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Peanut Allergy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Peanut Allergy pipeline products. Some of the key takeaways from the Peanut Allergy Pipeline Report Major companies such as Regeneron Pharmaceuticals, AnaptysBio, DBV Technologies, HAL Allergy, Astellas Pharma, Mast Cell Pharmaceuticals, Vedanta Biosciences, Inc., Cour Pharmaceutical Development, Prota Therapeutics, Novartis/Genentech, Allergy Therapeutics, Alladapt Immunotherapeutics, Intrommune Therapeutics , Camallergy, and others are developing potential drug candidates to improve the Peanut Allergy treatment scenario. In 2020 the FDA rejected DBV Technologies'' for peanut allergy treatment.
   AnaptysBio EPS beats by $0.12, beats on revenue  2021/08/09 21:06:35 Seeking Alpha
   AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference  2021/05/27 00:00:00 BioSpace
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference
   AnaptysBio Inc. Shares Close the Week 30.4% Lower - Weekly Wrap  2021/03/05 22:30:00 Kwhen Finance
AnaptysBio Inc. shares closed this week 30.4% lower than it did at the end of last week. The stock is currently down 9.3% year-to-date, up 7.0% over the past 12 months, and up 14.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 fell 2.0%. Trading Activity Shares traded as high as $29.63 and as low as $18.25 this week.Trading volume this week was 389.3% higher than the 10-day average and 878.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -128.8% The company's stock price performance over the past 12 months lags the peer average by -88.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   AnaptysBio Inc. Shares Close the Week 20.6% Higher - Weekly Wrap  2021/02/12 22:30:00 Kwhen Finance
AnaptysBio Inc. shares closed this week 20.6% higher than it did at the end of last week. The stock is currently up 63.9% year-to-date, up 130.4% over the past 12 months, and up 107.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.5%. Trading Activity Shares traded as high as $35.85 and as low as $28.47 this week.Shares closed 2% below its 52-week high and 2e+2% above its 52-week low.Trading volume this week was 92.9% higher than the 10-day average and 144.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -27.7% The company's stock price performance over the past 12 months lags the peer average by -9.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   AnaptysBio Inc. Shares Near 52-Week High - Market Mover  2021/02/12 22:30:00 Kwhen Finance
AnaptysBio Inc. shares closed today at 1.7% below its 52 week high of $35.85, giving the company a market cap of $963M. The stock is currently up 63.9% year-to-date, up 130.4% over the past 12 months, and up 107.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.5%. Trading Activity Trading volume this week was 144.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -27.7% The company's stock price performance over the past 12 months lags the peer average by -9.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference  2021/05/27 00:00:00 BioSpace
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Jefferies Virtual Healthcare Conference
   AnaptysBio Inc. Shares Close the Week 30.4% Lower - Weekly Wrap  2021/03/05 22:30:00 Kwhen Finance
AnaptysBio Inc. shares closed this week 30.4% lower than it did at the end of last week. The stock is currently down 9.3% year-to-date, up 7.0% over the past 12 months, and up 14.8% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 fell 2.0%. Trading Activity Shares traded as high as $29.63 and as low as $18.25 this week.Trading volume this week was 389.3% higher than the 10-day average and 878.4% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -128.8% The company's stock price performance over the past 12 months lags the peer average by -88.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   AnaptysBio Inc. Shares Close the Week 20.6% Higher - Weekly Wrap  2021/02/12 22:30:00 Kwhen Finance
AnaptysBio Inc. shares closed this week 20.6% higher than it did at the end of last week. The stock is currently up 63.9% year-to-date, up 130.4% over the past 12 months, and up 107.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.5%. Trading Activity Shares traded as high as $35.85 and as low as $28.47 this week.Shares closed 2% below its 52-week high and 2e+2% above its 52-week low.Trading volume this week was 92.9% higher than the 10-day average and 144.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -27.7% The company's stock price performance over the past 12 months lags the peer average by -9.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   AnaptysBio Inc. Shares Near 52-Week High - Market Mover  2021/02/12 22:30:00 Kwhen Finance
AnaptysBio Inc. shares closed today at 1.7% below its 52 week high of $35.85, giving the company a market cap of $963M. The stock is currently up 63.9% year-to-date, up 130.4% over the past 12 months, and up 107.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.5%. Trading Activity Trading volume this week was 144.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -27.7% The company's stock price performance over the past 12 months lags the peer average by -9.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アナプティスバイオ ANAB AnaptysBio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)